Skip to main content
. 2013 Oct;87(20):10955–10967. doi: 10.1128/JVI.01164-13

Fig 4.

Fig 4

BALB/c mice were challenged with rA2-line19F (1 × 106 TCID50) with or without the administration of 131-2G F(ab′)2, intact 131-2G, or normal, or control, immune globulin (nIgG) 2 days earlier (n = 5 mice/group). (A) Effect of anti-RSV G protein MAb 131-2G treatment on changes in breathing effort in BALB/c mice. Breath-associated changes in the distension of peripheral arteries in microns (breathing effort) was measured at 8 days p.i. (B) Effect of prophylactic administration of anti-RSV G protein MAb 131-2G on viral load. (C) Effect of prophylactic administration of anti-RSV G protein MAb 131-2G on BAL cell numbers. Data are means ± SEMs. ***, significant decrease (P ≤ 0.001; ANOVA) in virus titer compared to that for challenged, untreated mice (rA2-line 19F). The results for 131-2G F(ab′)2 and rA2-line19F are representative of two independent experiments.